It’s death after a RS. Wait for 4.00 or way under. Then Good risk reward
Happy I hit and run. I would consider this at under 4.00
They definite are diluting. They need money. But in long run great for shareholder
highest volume in history -insert dd-
WHAT NEWS ??????
I’d be nice waking up to thirty bucks a share from this level
Next week it should run strong.
This news is very positive
Insiders are buying options. Time to load imo. Could see 2.00-3.00 like nothing
I'm with you on this one and so are the Baker Bros
Never seen a board that nobody post wtf. Lol. We got things coming imo
2 million volume yesterday. That’s a fund imo. I told you this was coming. Price of a stock does not reflect market value. This combo of drugs is a monster. I see 5-15.00 by Jan 2025
In addition to the progress with avutometinib + defactinib in LGSOC ONCT is moving two KRAS-G12C projects forward: avutometinib + sotorasib and avutometinib + adagrasib in KRAS-(G12C) NSCLC. Preclinical data suggests that we should see synergy with these combinations. I believe that the avuto + soto initial readout should happen at any time and this will be a big deal if the data is encouraging. In the preclinical data VSTM demonstrated that the synergistic effect of avutometinib + a G12C inhibitor was further enhanced with the addition of defactinib. I hope that they advance this G12C program with both the doublet and the triplet approach.
Clinical progress with the LGSOC program and the KRAS-G12C programs justify a much higher market cap than we have now. Any success with pancreatic cancer would be a total game-changer. The LGSOC and KRAS-G12C programs and low market cap provide a low risk opportunity to be in on the big prize which is Pancreatic cancer.
The RAMP201 and FRAME data for LGSOC is excellent so far. We should have final data readout in about 18 months (IMO). This data is expected to support an AA filing with the FDA for LGSOC. The current PPS does not reflect the significance of this. In addition, we have near term pending data on RAMP203 for RAS(G12C) NSCLC. Positive results with RAMP203 will further enhance value and help establish Avutometinib as a valid approach to RAS pathway cancers.
As an aside, I have my eyes on Akena's RAF:MEK clamp which may be even better than Avutometinib. The only problem is that Akena's molecule is several years behind Avuto in development.
I think that anyone interested needs to follow-up reading this PR by listening to the webcast presentation. It provides a more granular and encouraging overview than the PR alone does. I felt much more encouraged after hearing the overview and seeing the slides.
For instance the 28% ORR is interim data, not fully matured data. If one includes the 3 unconfirmed PRs the ORR is 38%. That's very good. If approved there will be TWO drugs approved.
Regulatory Update Following Type B FDA Meeting on LGSOC Program
A recent FDA meeting was held to discuss the encouraging results to date of the ongoing RAMP 201 trial evaluating avutometinib ± defactinib among patients with recurrent LGSOC, confirm the go forward treatment regimen selection and discuss the regulatory path forward. The combination of avutometinib with defactinib has been selected vs monotherapy as the go forward treatment in all recurrent LGSOC regardless of KRAS status, acknowledging the demonstrated contribution of defactinib.
The Company intends to include mature data from RAMP 201, the Verastem sponsored clinical trial, and the FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust to potentially support filing for accelerated approval. Both studies are evaluating avutometinib and defactinib in patients with recurrent LGSOC. The Company is in ongoing discussions with the FDA on the confirmatory study and plans to provide an update after agreement with the FDA. Continued enrollment in the combination arm of RAMP 201 is planned to expand the clinical experience in anticipation of initiation of a confirmatory study.
“We appreciate the productive and ongoing discussions with the FDA regarding the progress of our LGSOC program, including the alignment around key next steps as part of our breakthrough therapy designation,” said Brian Stuglik, CEO of Verastem Oncology. “With the encouraging results of the RAMP 201 Part A interim analysis and the FRAME study, we will work expeditiously to prepare to file for an accelerated approval that encompasses the totality of the data from both trials as well as progress on the confirmatory study.”
I already one a nice chunk. Listened to the webcast. Data looks very impressive. Open to discussing it.
Looks like Big mews coming in next 3-6 months
Nobody posts. But i know its coming. Boommmmmmm
I thinkthis is a HR. 90 mil cash. At these prices look in 5 years. 10-20x money. They drug is good iMo
What is going on here
People can sell….I keep buying. I been following VSTM For 7 years+ this is a Real biotech. Not some start up. Cash Heavy molecule Top notch future
This is buyout canidate. 4 trisls. Plenty of cash
Just got involved recently. Plenty of cash and upcoming catalysts.
Anything new on this:
The company announced they completed enrollment in Part A of RAMP 201 of VS-6766 +/- Defactinib in LGSOC. They anticipate report results from Part A in Q2.
There is so much here. Cant believe this isnt 3.00
$VSTM Chart waking up here..on watch this week..